U.S. biotech companies Alnylam, Dicerna settle trade secrets case

Uber CEO and transport boss had second meeting over London license battle
April 20, 2018
Twitter bans ads from Russia’s Kaspersky Lab
April 20, 2018
This post was originally published on this site

BOSTON (Reuters) – Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.